

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/168385 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61K 31/519* (2006.01)
A61K 9/00 (2006.01) *A61K 31/555* (2006.01)
A61K 9/08 (2006.01) *A61K 47/38* (2006.01)
A61K 31/4745 (2006.01) *A61P 35/00* (2006.01)
A61K 31/513 (2006.01)

(21) International Application Number:

PCT/AU2024/050096

(22) International Filing Date:

14 February 2024 (14.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023900354 14 February 2023 (14.02.2023) AU

(71) Applicants: **AMPLIA THERAPEUTICS LIMITED** [AU/AU]; Level 17, 350 Queen Street, Melbourne, Victoria 3000 (AU). **GARVAN INSTITUTE OF MEDICAL RESEARCH** [AU/AU]; 384 Victoria Street, Darlinghurst, New South Wales 2010 (AU).

(72) Inventors: **LAMBERT, John**; c/- Level 17, 350 Queen Street, Melbourne, Victoria 3000 (AU). **DEVLIN, Mark**; c/- Level 17, 350 Queen Street, Melbourne, Victoria 3000 (AU). **COCK, Terrie-Anne**; c/- Level 17, 350 Queen Street, Melbourne, Victoria 3000 (AU). **TIMPSON, Paul**; c/- 384 Victoria Street, Darlinghurst, New South Wales 2010 (AU). **HERRMANN, David**; c/- 384 Victoria Street, Darlinghurst, New South Wales 2010 (AU). **MURPHY, Kendelle**; c/- 384 Victoria Street, Darlinghurst, New South Wales 2010 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level 19, South Tower, 80 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMBINATION THERAPY

(57) Abstract: The present invention is directed to a combination treatment regimen of a FAK inhibitor (FAKi) with a FOLFIRINOX chemotherapy treatment regimen, and the use of that treatment regimen as a means of treating cancer in a patient in need thereof, particularly patients with fibrotic cancers/tumours such as pancreatic cancer.

WO 2024/168385 A1